SOT106: Novel, Best-in-Class ADC for Sarcomas & LRRC15-Positive Tumors
Certis Oncology is honored to have supported SOTIO Biotech with breakthrough data presented on SOT106, a novel ADC that targets leucine-rich repeat containing protein 15 (LRRC15), which is commonly overexpressed in mesenchymal malignancies. SOT106 is being developed for the treatment of patients with sarcomas and other LRRC15-positive tumors. The oral presentation at AACR featured new preclinical in vitro and in vivo data.
Custom PDX models, carefully executed pharmacology studies, and advanced imaging yielded deep insights into strong and durable tumor response to SOTIO’s innovative antibody-drug conjugate (ADC) program.
For more information on the SOT106 program, contact SOTIO Biotech at sotio@sotio.com.
“The MRI data Certis provided had a big impact, especially for physicians in the room. While graphs can tell the same story, showing images of actual tumor regression in situ proved to be very powerful. I’d like to sincerely thank you (Arunima), Howard, Fernando, Kristy, and the entire team for your flexibility, detailed updates, and ongoing consultations throughout the course of this study. Your support has been truly appreciated.”
- Michaela Fojtů, Senior Scientist, SOTIO Biotech
CertisOI Assistant™ - Accelerating Preclinical Cancer Model Selection with Generative AI
Preclinical oncology researchers face challenges identifying suitable tumor models, often limited by rigid database search systems. To address this critical need, Certis Oncology introduces CertisOI Assistant™, a Generative AI-powered platform enabling natural language queries and dynamic model selection from an integrated database of proprietary patient-derived xenograft (PDX) models and the Cancer Cell Line Encyclopedia (CCLE).
CertisOI™ uniquely integrates with the CertisAI™ platform to predict drug responses, empowering researchers to choose models based on predicted sensitivity or resistance to FDA-approved therapies. Powerful data integrations, interactive real-time analyses, and iterative refinement of queries streamline the model selection process, accelerating translational research from preclinical studies to clinical applications.
The AACR Debut of CertisOI Assistant™
A big shoutout to our lead developer, Luke Jervis, for delivering an intuitive, easy-to-use generative and agentic AI tool to help Certis clients source optimal preclinical tumor models. CertisOI Assistant draws on deep characterization data housed in our own cancer model database, BarneyOI®, as well as the entire Cancer Cell Line Encyclopedia (CCLE). It also taps into the power of CertisAI™, our recently patented, predictive AI/ML platform. Luke presented his poster to a highly engaged audience of researchers on Tuesday.
Congratulations to all presenters at this year’s AACR! See you next year.
CLIA-Certified
AAALAC Accredited
OLAW Accredited
Your Translational Partner
Certis Oncology Solutions is an AI-enabled life science technology company committed to accelerating the development of new cancer therapies and realizing the promise of precision oncology. Our product is Oncology Intelligence® — highly predictive therapeutic response data derived from advanced biological models of cancer and enhanced with CertisAI™ Predictive Oncology Intelligence. Certis partners with therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials.
Through more clinically relevant, well-characterized and annotated cancer models, advanced imaging technology, including x-ray irradiation with image-guided radiation therapy, and thoughtfully designed custom studies, our proprietary platform brings greater certainty to go/no-go drug development decisions.
